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Asthma Intervention Research

AIR2

Asthma Intervention Research 2

AQLQ

Asthma Quality of Life Questionnaire

ATS

American Thoracic Society

BL

Baseline

BMI

Body mass index

BT

Bronchial thermoplasty

Eos

Eosinophils

ED

Emergency department

ERS

European Respiratory Society

FDA

Food and Drug Administration

FEV1

Forced expiratory volume in one second

FVC
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GLM

Generalized linear model
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Inhaled corticosteroids

LABA

Long-acting -agonist

mL

milliliters

NAEPP

National Asthma Education and Prevention Program

Neu

Neutrophils
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OCS

Oral corticosteroids
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Randomized controlled trial
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Research in Severe Asthma
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ABSTRACT
Background: Bronchial thermoplasty is a device-based treatment for subjects ≥18 years with
severe asthma poorly controlled with inhaled corticosteroids and long-acting beta-agonists. The
Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent
Asthma (PAS2) study collected data on severe asthmatics undergoing this procedure.
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Research Question: What are the 5-year efficacy and safety results in severe asthmatics who

ro

have undergone bronchial thermoplasty?
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Study Design and Methods: This was a prospective, open-label, observational, multi-center

re

study conducted in the United States and Canada. Subjects aged 18-65, taking inhaled

lP

corticosteroids ≥1000μg/day (beclomethasone or equivalent) and long-acting -agonists

na

≥80μg/day (salmeterol or equivalent) were included. Severe exacerbations, hospitalization,

ur

emergency department visits, and medication usage were evaluated for the 12 months prior to

treatment.
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and at years 1-5 post-treatment. Spirometry was evaluated at baseline and at years 1-5 post-

Results: 284 subjects were enrolled at 27 centers; 227 subjects (80%) completed 5 years of
follow-up. By year 5 post-treatment, the proportion of subjects with severe exacerbations,
emergency department visits, and hospitalizations was 42.7%, 7.9%, and 4.8%, respectively,
compared to 77.8%, 29.4%, and 16.1% in the 12 months prior to treatment. The proportion of
subjects on maintenance oral corticosteroids decreased from 19.4% at baseline to 9.7% at 5
years. Analyses of subgroups based on baseline clinical and biomarker characteristics revealed a
statistically significant clinical improvement among all subgroups.
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Interpretation: Five years after treatment, subjects experienced decreases in severe
exacerbations, hospitalizations, emergency department visits and corticosteroid exposure. All
subgroups demonstrated clinically significant improvement, suggesting that bronchial
thermoplasty improves asthma control in different asthma phenotypes.
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Clinical Trial Registry: http://www.clinicaltrials.gov, NCT01350336
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Asthma is a chronic disease of the airways characterized by airway inflammation, excess mucus
production, airway hyperresponsiveness, and variable airflow obstruction. Ten percent of
patients have severe, poorly controlled disease despite optimal medical therapy. These patients
account for more than 80% of asthma-related healthcare costs.1-3
Bronchial thermoplasty (BT) is the only FDA-approved procedure for the treatment of asthma.
It is indicated for patients ≥18 years with severe persistent asthma not well controlled with

of

inhaled corticosteroids (ICS) and long-acting bronchodilators (LABA). BT employs

ro

radiofrequency energy to heat the airway walls in a controlled manner. The mechanism of action

-p

is attributed to a reduction in airway smooth muscle (ASM) mass after the procedure4-9.
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Reduction in ASM has been associated with clinical improvement seen in patients undergoing

lP

BT5,6. Other structural and immunohistological changes after BT, including reduction in

na

reticular basement membrane thickness, reduction in collagen type I deposition, and changes in

ur

neuroendocrine cells, may also contribute to clinical improvement4,6,10,11.

Jo

Several randomized controlled clinical trials (RCT) of BT have been carried out in subjects with
moderate to severe asthma – including the AIR, RISA, and AIR2 studies12-15. These studies
demonstrated improvements in asthma control following BT, including decreased numbers of
asthma exacerbations, ED visits, and hospitalizations. In addition, subjects experienced improved
quality of life as measured by Asthma Quality of Life Questionnaire (AQLQ) scores15. These
improvements persisted for at least 5 years and side effects were minimal14. Nevertheless, data
obtained from prospective studies with more clinically realistic eligibility criteria than those
defined by previous RCTs can provide reassurance that these results can be duplicated in clinical
practice, which often includes subjects with more severe disease.

5

Following FDA approval in 2010, the “Post-FDA Approval Clinical Trial Evaluating BT in
Severe Persistent Asthma (PAS2)” study was initiated. An interim analysis of data from the first
190 PAS2 subjects confirmed previous reports that BT is safe and effective16. Although the
PAS2 subjects were sicker than those in the AIR2 trial (94.7% of PAS2 subjects vs. 82.1% of
AIR2 subjects were classified as severe asthmatics based on the ERS/ATS guidelines), the
results from these 190 PAS2 subjects were comparable to those from the 190 BT subjects studied

of

in AIR2. PAS2 subjects had reduced rates of exacerbations, hospitalizations and ED visits at 3

ro

years post-BT compared to the 12 months prior to BT, indicating a consistent and durable

-p

treatment effect. This analysis also showed, for the first time, that patients sustainably reduced

re

asthma medication post-BT, including complete discontinuation of maintenance oral

lP

corticosteroids (OCS) in a significant proportion of subjects.

na

Here, we describe the clinical outcomes over five years following BT for the full cohort of 284

ur

PAS2 subjects. Analyses of subgroups based on baseline clinical and biomarker characteristics

Jo

were also performed to investigate potential correlations with responses to BT.

METHODS
Study Design
The PAS2 study design has been previously published16. PAS2 was a prospective, open-label,
observational, multi-center clinical study (NCT01350336; clinicaltrials.gov) to investigate the 5year efficacy and safety of BT. The study was approved by the Ethics committee at each
participating site and all subjects signed an informed consent form prior to participation. The
last subject exited the study in November 2019 after completing the 5-year follow-up visit.
6

Study Subjects
Between 2011 and 2014, PAS2 enrolled subjects between 18-65 years whose asthma was
inadequately controlled despite optimized treatment with high ICS and LABA doses (ICS ≥1000
μg/day [beclomethasone or equivalent] and LABA ≥80 μg/day [salmeterol or equivalent]).
Subjects were allowed asthma medications in addition to ICS and LABA/SABA (short-acting
beta-agonists), including OCS and/or omalizumab. Subjects diagnosed with other severe

of

respiratory diseases were excluded. Other eligibility criteria for PAS2 have been previously

-p

ro

described16.

re

Treatment

lP

BT treatments were administered using the AlairTM Bronchial Thermoplasty System (Boston

na

Scientific, Marlborough, MA) per FDA labeling by the investigators as previously described14,15.

ur

Follow-up

Jo

PAS2 subjects were evaluated 2 weeks following each of the first 2 BT procedures and 6 weeks
after the third (the end of the treatment period). Subjects were scheduled to be seen at annual inperson visits for 5 years after the BT treatments and by phone every 3 months between visits.
Outcome Measures
The primary objective of PAS2 was to demonstrate the durability of treatment effect after BT.
Severe asthma exacerbations, ED visits, and hospitalizations for respiratory symptoms during the
5 years after BT were compared to the respiratory events which occurred during the 12-month
period prior to BT. Severe exacerbations were defined as a worsening of asthma symptoms
requiring the use of systemic corticosteroids (tablets, suspension, or injection; for further details,
7

see Supplementary Methods 1)17. Other outcome measures used in PAS2 have been previously
described16.
Adverse Event Monitoring
Adverse events were collected peri-procedurally (defined as the period beginning on the day of
the first BT procedure and ending 6 weeks after the last BT procedure) and at each follow-up

of

visit in the post-treatment period. For further description of how adverse events were defined, see

ro

Supplementary Methods 1.

-p

Statistical Analyses

re

Baseline demographics, clinical characteristics, and outcomes were summarized with sample

lP

size, mean, standard deviation, minimum and maximum for continuous variables and with

na

proportions (numerator over denominator) for binary variables. To compare proportions, counts
of events, and doses between baseline and years 1-5, the Fisher’s exact test, negative binomial

ur

test and t-test were used, respectively. For the subgroup analyses, a generalized linear model

Jo

(GLM) with binomial or negative binomial error distribution was fit with factors of the
subgroup, time and interaction of subgroup and time; if the interaction had a p-value<0.10,
contrasts of time within subgroup and subgroup within time were performed to explore
differences. SAS version 9.4 was used for all analyses.
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RESULTS
Baseline demographics and clinical characteristics
Of 284 subjects enrolled, 279 (mean age 45.7±11.6 years) underwent BT as previously
described16, and 227 (81%) subjects completed 5 years of follow-up (Supplementary Figure 1).
Subjects were 64.5% female with mean body mass index (BMI) 32.2±7.5 kg/m2, and were 84%

of

Caucasian, 9% black or African heritage, and 7% from other racial groups. Subjects had mean

ro

AQLQ score of 4.03±1.28, had asthma diagnosis on average 25.2 years prior to BT, and based

-p

on the ERS/ATS Guidelines for Severe Asthma18, 95% of subjects were considered severe

re

asthmatics (Table 1).

lP

Baseline demographics were similar between the 227 subjects followed for 5 years and the 52

na

subjects who were not. A larger proportion of the subjects not followed for 5 years experienced

ur

severe exacerbations (92.3% vs. 74.4%), ED visits (51.9% vs. 24.2%), and hospitalizations

Jo

(30.8% vs. 12.8%) during the 12 months before BT compared to the 227 subjects followed for 5
years (Table 2). This indicates that the subjects who dropped out of the PAS2 study may have
had more severe disease and thus some subjects with the most severe asthma were not included
in the analysis.
Severe asthma exacerbations, ED visits, and hospitalizations
During the 12 months prior to BT, 77.8% of subjects experienced at least one severe
exacerbation, compared to 50.4% after 1 year, 46.8% after 2 years, 47.0.% after 3 years, 44.2%
after 4 years, and 42.7% after 5 years of follow-up (77.8% vs. 50.4%, 46.8%, 47.0%, 44.2%, and
42.7%, p<0.001) (Table 1 and Figure 1). There was also a significant reduction in the rate of

9

severe exacerbations from baseline (1.61 exacerbations/subject) to 5 years (0.72
exacerbations/subject; p<0.001). There were 61.8% (68/110) subjects with ≤1 severe
exacerbations during the 12 months prior to BT who experienced ≤1 severe exacerbation per
year following BT treatment compared to 35.0% (41/117) subjects with ≥2 severe exacerbations
during the 12 months prior to BT (Table 3).
The proportion of subjects with ED visits significantly decreased from 29.4% during the 12

of

months prior to BT to 18.3%, 14.7%, 13.0%, 11.7%, and 7.9% during Years 1 through 5,

ro

respectively, after BT (p< 0.001) (Figure 1). ED visit rates were also reduced from 0.54 ED

-p

visits/subject in the 12 months prior to BT to 0.13 ED visits/subject in Year 5 (p=0.0002). A

re

decrease in hospitalizations was also observed after BT (Figure 1); 16.1% of subjects were

lP

hospitalized for asthma in the year prior to BT, but during Years 1-5, only 8.0%, 7.5%, 7.3%,

na

3.3%, and 4.8%, respectively, were hospitalized (p=0.0003). Annual hospitalization rates fell

ur

from 0.22 hospitalizations/subject at baseline to 0.06 hospitalizations/subject at Year 5 after BT

Jo

(p=0.0012).

The PAS2 data confirms reductions in these outcomes demonstrated in the AIR2 study (Figure
1).
Spirometry
Spirometry was performed at baseline and at yearly follow-up visits for all subjects. BT did not
alter spirometric parameters as reported in previous studies6,14,19,20 (Supplementary Figure 2).
Medication usage

10

PAS2 subjects reduced asthma maintenance medications. Notably, clinical improvements were
accompanied by a reduction in corticosteroid exposure. The mean daily ICS dose of 2272 μg/day
(beclomethasone or equivalent) at baseline was sustainably reduced to 1928 μg/day, by Year 5
post-BT (Table 4).
The percentage of subjects using biologic medications for asthma control remained relatively
constant (15.8%-18.5%) over the course of the study (Table 4). At baseline, omalizumab was

of

used exclusively. In subsequent years, some subjects began using mepolizumab, benralizumab,

-p

ro

and reslizumab as these monoclonal antibodies were introduced (Table 4).

re

Additionally, 54 (54/279: 19.4%) subjects were taking maintenance OCS at the baseline visit.

lP

After BT treatment, 10.7%, 10.2%, 10.0%, 8.1%, and 9.7% of subjects were taking maintenance
OCS at the 1-5-year follow-up visits, respectively (Table 4). Twenty-two (42%) of the 54

na

subjects taking OCS at baseline discontinued OCS after BT (Figure 2), and only 6 of these 22

ur

subjects then used a biologic. The proportion of subjects with severe exacerbations among those

Jo

22 fell from 95.5% at baseline to 50.0% at Year 5 following BT treatment (Figure 2). In these
subjects BT not only reduced OCS exposure, but also severe exacerbations, ED visits and
hospitalizations.
Clinical improvements in the 32 subjects who continued taking OCS medications after BT were
similar. In this case, 18/32 subjects also used a biologic for asthma maintenance. The proportion
of the 32 subjects experiencing severe exacerbations was reduced from 93.8% at baseline to
51.9% at Year 5 after BT. These reductions in the proportion of subjects experiencing severe
exacerbations were comparable to subjects who never used maintenance OCS (73.3%

11

experienced severe exacerbations at baseline vs. 42.7% at Year 5 after BT), even though patients
using maintenance OCS may have had more severe disease at baseline (Figure 2).
Only 9 subjects who were not taking OCS at baseline began taking these medications for asthma
control after BT. These patients did not experience a reduction in severe exacerbations.
Adverse Events
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Bronchoscopic procedures can worsen asthma-related symptoms in the short term and induce

ro

other complications in severe asthmatics21-23. While the percentage of subjects with peri-

-p

procedural respiratory serious AEs (requiring hospitalization or prolongation of hospitalization)

re

during the treatment phase was 14.7% (Table 5), respiratory serious AEs were reduced during

lP

the post-treatment phase to 9.4% during Year 1 after BT and to 4.7% during Year 5 after BT.

na

During this study, 4 deaths, all unrelated to BT, occurred. Two males, aged 50 and 55 years,
died of cardiac arrest. The 55-year-old male was found unresponsive (pulseless and asystolic) at

ur

home approximately 3 years after the third BT procedure. The 50-year-old male died of cardiac

Jo

arrest shortly after completing the third BT treatment. A 57-year-old female subject died of
myocardial infarction approximately two years after the final BT treatment after cardiac
catheterization/stenting for severe arterial stenoses failed. A 53-year-old male died
approximately 3 years after his last BT procedure of unknown causes. This subject had severe
obstructive sleep apnea and died in his sleep; no autopsy was performed.
Subgroup analysis
We analyzed subgroups of subjects to see if BT was effective in reducing severe exacerbations,
ED visits, and hospitalizations. Subgroups included: gender, age (<40 and ≥40 years), BMI (<30
and ≥30 kg/m2), baseline AQLQ (<4.0 and ≥4.0), baseline OCS use (yes and no), baseline
12

omalizumab use (yes and no), and complete activations (≤140 and >140). We also analyzed
subgroups based on baseline pre-bronchodilator FEV1/FVC (≤70% and >70%), and
bronchodilator reversibility (fixed or reversible)24, as well as baseline blood counts of
eosinophils (≤150 and >150 cells/μL), neutrophils (≤5000 and >5000 cells/μL), and both
eosinophils and neutrophils (both eosinophils ≤150 cells/μL and neutrophils ≤5000 cells/μL and

of

at least one of eosinophils >150 cells/μL or neutrophils >5000 cells/μL)25-27.

ro

Our analysis indicated there was a significant decrease in severe exacerbations, ED visits, and

-p

hospitalizations over time for all sets of subgroups (Figure 3, Supplemental Table 1,

re

Supplemental Figure 3; for more detail see Supplemental Results 1), showing that all

na

lP

examined subgroups of subjects benefitted from BT.

For subgroups based on blood eosinophil and neutrophil counts, significant differences in the

ur

percentages of subjects experiencing hospitalizations and severe exacerbations after BT were

Jo

observed in the subgroups based on baseline blood eosinophil and neutrophil counts,
respectively. There were no differences in subgroups based on both baseline blood eosinophil
and neutrophil counts (Figure 4). Subjects with eosinophil counts of ≤150 cells/µL had
consistently higher percentages of subjects experiencing hospitalizations than subjects with
eosinophil counts >150 cells/µL in the 12 months before and in the years following BT
treatment. Subjects with neutrophil counts ≤5000 cells/µL had consistently lower percentages of
severe exacerbations than subjects with neutrophil counts >5000 cells/µL in the years following
BT treatment, but not during the 12 months before BT. (Figure 4, middle and bottom).
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DISCUSSION

With 284 patients enrolled, PAS2 is the largest study to date designed to evaluate the
effectiveness and safety of BT and the durability of treatment effect in subjects with poorly
controlled asthma despite treatment with the current standard of care. Previous clinical trials of
BT (AIR, AIR2, and RISA) have shown that the procedure is safe and effective, but subjects
enrolled in these clinical trials may not be representative of the most severe asthma cases

of

considered for BT in clinical practice. For example, the AIR2 RCT excluded patients with

ro

insulin-dependent diabetes, interstitial lung disease, chronic sinus disease, obstructive sleep

-p

apnea, and other common comorbidities found in asthmatics, but the PAS2 study allowed

re

participation of subjects with these conditions. Recent publications have reported on BT in more

lP

severe asthmatics that were older and had worse baseline lung function and quality of life4,6-8,28.

na

The data indicated a clinical improvement post-BT in these subjects as well as acceptable rates

ur

of adverse events. Additionally, Chaudhuri et. al. recently reported that the clinical

Jo

improvements following BT can last for 10 or more years after treatment in some subjects29.
PAS2 adds to the body of evidence demonstrating the long-term safety and effectiveness of BT
outside the setting of RCTs.
While PAS2 is a single-arm study, the findings are important and confirm previously published
interim results in this population16, indicating that clinically relevant improvements in asthma
control (particularly significant reductions in severe exacerbations) are sustainable to 5 years of
follow-up.
The severe asthmatics in PAS2 had relatively well-preserved pulmonary function (FEV1 in the
75-80% range)30. Asthmatics, particularly those with severe asthma, experience a progressive

14

decline in lung function as measured by FEV1 with time (22.5-50 mL/year). Subjects who
experience more severe exacerbations per year tend to exhibit a more rapid decline in FEV130-33.
As in previous publications14-16, there is no significant decline in FEV1 and FVC out to 5 years
following BT, highlighting the long-term safety of the BT procedure.
In PAS2, 14.7% of subjects experienced procedure-related SAEs during the treatment period.
This was slightly higher than in previously reported trials of BT14,34, perhaps due to enrollment

of

of subjects with more severe asthma and more comorbidities in PAS2. The most common peri-

ro

procedural respiratory SAE was asthma aggravation (77.8%), due in part to the length of the

-p

bronchoscopic procedure required and/or the thermal injury sustained during the procedure.

re

While hospitalization was required for all peri-procedural respiratory SAEs, intubation and/or

lP

mechanical ventilation was reported in only 4 cases, 2 due to hemoptysis. One occurred one

na

week after the second BT treatment; the subject was intubated, underwent bronchoscopy to

ur

suction a blood clot, and had the third BT treatment. The second occurred one month after the

Jo

third BT procedure; the subject was intubated, an embolization procedure was performed, and
the subject completed follow-up. A third subject experienced vocal cord spasm 30 minutes after
the first BT treatment and required intubation until the spasm resolved; the subject recovered but
did not undergo further BT treatments. The last subject experienced an asthma exacerbation
requiring intubation in the ED one day after the second BT treatment; the subject recovered and
completed the third BT treatment, but withdrew before the 3-year follow-up.
PAS2 subjects were able to reduce exposure to corticosteroid medications, particularly OCS,
after BT. Forty-two percent of subjects on OCS were able to completely discontinue them after
BT treatment while simultaneously improving asthma control. This is encouraging, as daily use
of OCS is associated with significant side effects and negative impact on quality of life35. This
15

suggests that BT should be considered as a treatment option for patients who are taking systemic
corticosteroids and are experiencing or concerned about these side effects36.
Although we were unable to identify a specific subgroup of patients in which BT was most
effective using baseline data, it is important to note that BT was effective in all subgroups,
including subjects with both fixed and reversible airways and both high and low eosinophil
counts. Interestingly, patients with low blood eosinophil counts responded favorably to BT,

of

suggesting that BT can be considered as a treatment option for patients that are not candidates for

-p

ro

a biologic therapy37,38.

re

One limitation of the PAS2 study was that it did not include a sham or control group, and the

lP

effect of closer follow-up of patients in the setting of a clinical study on potential medication
reductions and improvement in asthma control cannot be ruled out. Another limitation is that, as

na

in all open-label extension studies, the subjects who were not followed for the entire 5-year

ur

period tended to be more severe asthmatics with worse prognosis, which introduced bias. While

Jo

changes in quality-of-life scores (AQLQ) would have been useful to present, AQLQ scores were
only collected at baseline in PAS2 and we were unable to analyze the effect BT had them. The
PAS2 subjects were heterogeneous in terms of asthma phenotype, and the subgroup analysis
based on asthma phenotype was post-hoc and based on counts of blood eosinophils and
neutrophils taken at baseline for a subset of subjects. However, it has been hypothesized that
sputum cellular profiles may be a more accurate measure of the type of inflammation occurring
in the airways, as blood counts of eosinophils and neutrophils may not always correlate perfectly
with sputum cellular profiles37. This limited our ability to accurately phenotype the subjects.
Studies in which asthma phenotype is more clearly defined are required to determine whether
certain types of asthma respond better to BT. Finally, as we did not compare responses after BT
16

to responses to biologics, it is not known whether the response to biologics in this study
population would have been more pronounced than the response to BT. It is possible that since
biologics selectively target pro-inflammatory pathways, and BT largely acts on processes
involved in airway remodeling, the two treatments could be complementary in severe asthmatics
with evidence of both airway inflammation and airway remodeling. We did observe that BT was
safe and improved clinical outcomes regardless of whether or not biologic medications,

of

including those targeting IL5, were initiated after treatment (data not shown); however, we

ro

recognize that the PAS2 study was not controlled and that the asthma treatment landscape is

-p

shifting, which is a challenge for all trials involving this disease.

re

INTERPRETATION

lP

Five years after treatment, PAS2 subjects experienced decreases in severe exacerbations,

na

hospitalizations, ED visits and corticosteroid exposure. Subgroup analyses suggested that BT

ur

improves asthma control in different asthma phenotypes. BT may be a valuable add-on therapy

Jo

for the treatment of severe asthma. It may also be a treatment option for severe asthmatics who
do not qualify for biologic therapy.

TAKE-HOME POINTS
Study Question: What are the 5-year efficacy and safety outcomes in severe asthmatics who
have undergone bronchial thermoplasty?
Results: Out of 284 subjects enrolled in the PAS2 study, 227 subjects (80%) completed 5 years
of follow-up. By year 5 post-treatment, the proportion of these subjects with severe
exacerbations, emergency department visits, and hospitalizations was 42.7%, 7.9%, and 4.8%,
respectively, compared to 77.8%, 29.4%, and 16.1% in the 12 months prior to treatment. The
17

proportion of subjects on maintenance oral corticosteroids decreased from 19.4% at baseline to
9.7% at 5 years. Subgroup analyses based on baseline clinical and biomarker characteristics
revealed a statistically significant clinical improvement among all subgroups, including those
based on eosinophil and neutrophil counts.
Interpretation: Five years after treatment, subjects experienced decreases in severe
exacerbations, hospitalizations, emergency department visits and corticosteroid exposure,

of

indicating clinically relevant improvements in asthma control. The subgroup analyses performed

ro

indicate BT may be a valuable add-on therapy for the treatment of subjects with severe asthma

-p

including those on OCS and omalizumab. BT may also be a treatment option for severe

re

asthmatics who cannot use or do not qualify for biologic therapy for asthma, such as those with

Jo

ur

na

lP

non-eosinophilic disease.
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FIGURE LEGENDS

Figure 1. Percent of subjects experiencing severe exacerbations, ED visits, and hospitalizations
(top panel) and the rates of these events (# events/subject, bottom panel) out to 5 years after BT.
Results from the AIR2 randomized controlled trial are shown for comparison; note that the
definition of “severe exacerbation” differed between the AIR2 trial and the PAS2 study.

of

Abbreviations: ED, emergency department.

ro

Figure 2. Clinical outcomes for different patterns of maintenance oral corticosteroid usage in

-p

PAS2 subjects. Abbreviations: BL, baseline; BT, bronchial thermoplasty; ED, emergency

re

department; OCS, oral corticosteroid.

lP

Figure 3. Subgroup analyses of major endpoints after BT for: male vs. female subjects (top

na

left), subjects aged ≤40 years vs. subjects aged ≥41 years (top right), subjects with BMI ≤30 vs.

ur

subjects with BMI >30 (middle left), subjects with baseline AQLQ scores ≤4.0 or less vs.

Jo

subjects with baseline AQLQ scores >4.0 (middle right), subjects not using OCS at baseline vs.
subjects using OCS at baseline (bottom left), and subjects not using omalizumab at baseline vs.
subjects using omalizumab at baseline (bottom right). Abbreviations: AQLQ, Asthma Quality
of Life Questionnaire; BL, baseline; BMI, body mass index; ED, emergency department; OCS,
oral corticosteroids; Oma, omalizumab; yrs, years.
Figure 4. Subgroup analyses of major endpoints after BT by baseline blood eosinophil counts
(middle right), baseline blood neutrophil counts (bottom left), and for subjects with
paucigranulocytic asthma (low blood eosinophil/low blood neutrophil) vs. those with high blood
eosinophil or high blood neutrophil counts (bottom right). Abbreviations: eos, eosinophils; ED,
emergency department; neu, neutrophils.
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TABLES
Table 1. Baseline Demographics and Characteristics – All Treated Subjects (N=279)
PAS2 (N=279)1
Demographics
Age (years)

45.7±11.6

Female

64.5% (180)

Body Mass Index [kg/m2]

32.2±7.5

Caucasian

83.9% (234)
9.0% (25)

Hispanic or Latino

2.9% (8)

Asian

1.4% (4)

-p

ro

Black, of African heritage

American Indian or Alaska native

1.1% (3)
1.8% (5)

Baseline Medication usage

SABA (puffs/day)

ur

Other Asthma Medications

na

LABA Dose (μg/day; salmeterol or
equivalent)

OCS (prednisone or equivalent)

Jo

Dose (mg/day)

lP

ICS Dose (μg/day; beclomethasone or
equivalent)

re

Other

Methylxanthines

2272±787 (278)

105.3±4063 (278)
2.4±1.5 (264)
19.4% (54)
8.8±2.8 (52)
5.0% (14)

Leukotriene Modifiers

49.5% (138)

Omalizumab

15.8% (44)

Other

26.2% (73)

Quality of Life Measurement
AQLQ

4.03±1.28

ERS/ATS Guidelines on Severe
Asthma2
Severe Asthmatics

95.0% (265)

Spirometry: FEV1
% predicted:
Measured (L):

Pre-BD

80.4±13.7

Post-BD

85.8±13.6

Pre-BD

2.57±0.65

Post-BD

2.74±0.66

Spirometry: FVC
% predicted:

of

Race / Ethnicity

Pre-BD

91.1±13.1
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Measured (L):

Post-BD

PAS2 (N=279)1
94.6±12.9

Pre-BD

3.66±0.90

Post-BD

3.79±0.92

Spirometry: FEV1/FVC
Pre-BD

70.9±9.6

Post-BD
Blood Lab (cells/μL)
Eosinophils
Basophils
Neutrophils
Lymphocytes
Monocytes
Medical History

72.9±9.7

Years since asthma diagnosis

25.2±14.9

ro

12 Months prior to BT: % Subjects

77.8% (217)

Hospitalizations for asthma

16.1% (45)

ED visits for asthma

29.4% (82)

re

-p

Severe Exacerbations

lP

12 Months prior to BT: #
Events/Subject
Severe Exacerbations

1.61±1.12
0.22±0.53
0.54±1.20

ur

na

Hospitalizations for asthma
ED visits for asthma

of

285.6±262.1 (264)
44.3±43.2 (264)
5026±1956 (263)
2150±663 (264)
581.5±198.4 (264)

Jo

Abbreviations: ATS, American Thoracic Society; AQLQ, Asthma Quality of Life Questionnaire; BD,
bronchodilator; BT, bronchial thermoplasty; ED, emergency department; ERS, European Respiratory
Society; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled
corticosteroids; LABA, long-acting -agonist; OCS, oral corticosteroids; SABA, short-acting -agonists;
SE, severe exacerbation.
1

– Numbers are: mean ± standard deviation (sample size if <279) or % (x) or % (x/N) if sample size <279

– Based on ERS/ATS Guidelines for Severe Asthma, and due to the limitations of the PAS2 data, we
have defined subjects as having Severe Asthma if one of the following is true:
2






ICS≥2000 μg/day beclomethasone or equivalent and either LABA or Leukotriene Modifier usage,
or
≥2 SE in 12 months prior to first BT treatment, or
≥1 hospitalization in 12 months prior to first BT treatment, or
post-BD FEV1<80% and FEV1/FVC<0.7.
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Table 2. Baseline Demographics and Characteristics – Comparison of Terminated Subjects and Subjects
Followed for 5 Years

1.9% (1/52)
0.0% (0/52)
7.7% (4/52)
80.8% (42/52)
5.8% (3/52)
3.8% (2/52)
33.21±7.71 (52)

0.9% (2/227)
1.8% (4/227)
9.3% (21/227)
84.6% (192/227)
2.2% (5/227)
1.3% (3/227)
31.97±7.40 (227)

0.51
0.34
0.72
0.50
0.16
0.22
0.28

2302.03±783.66 (226)
105.90±40.00 (225)

0.18
0.82

p-value
0.027
0.27

2.38±1.58 (216)

0.73

25.0% (13/52)
10.00±2.04 (13)
3.8% (2/52)
53.8% (28/52)
13.5% (7/52)
44.2% (23/52)

18.1% (41/227)
8.35±2.89 (39)
5.3% (12/227)
48.5% (110/227)
16.3% (37/227)
39.2% (89/227)

0.25
0.062
0.67
0.66
0.61
0.24

80.8% (42/52)

74.4% (169/227)

0.34

3.63±1.25 (52)

4.12±1.27 (227)

0.013

2.63±0.62 (52)
82.91±12.74 (52)

2.55±0.65 (227)
79.82±13.91 (227)

0.47
0.14

2.83±0.64 (52)
89.49±12.41 (52)

2.72±0.67 (227)
84.93±13.80 (227)

0.26
0.03

24.94±16.87 (52)

25.29±14.45 (227)

0.88

13.5% (7/52)

18.9% (43/227)

30.8% (16/52)
0.44±0.73 (52)

12.8% (29/227)
0.16±0.46 (227)

lP

2.29±1.22 (48)
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2141.15±798.01 (52)
104.12±42.01 (52)

of

Subjects Followed for 5
Years
(N = 227)
46.44±11.46 (227)
63.0% (143/227)

na

Variable
Age (yr)
Female
Ethnicity and Race
American Indian or Alaska native
Asian
Black, of African heritage
Caucasian
Hispanic or Latino
Other
BMI (kg/m2)
Medication usage
ICS Dose (μg/day)
LABA Dose (μg/day)
Short-acting beta agonists
(puffs/day)
Other Asthma Medications
OCS
Dose (mg/day)
Methylxanthines
Leukotriene Modifiers
Omalizumab
Other
Any of the above maintenance
medications
Other measures
AQLQ
FEV1
Pre-bronchodialator
Measured value (liters)
% predicted
Post-bronchodialator
Measured value (liters)
% predicted
Length of time diagnosed with
asthma (years)
Former Smoker
Hospitalizations for asthma in the 12
months prior to study entry
% subjects with hospitalizations
# hospitalizations

Terminated
Subjects
(N = 52)
42.50±11.89 (52)
71.2% (37/52)

0.0015
0.0005

32
Subjects Followed for 5
Years
(N = 227)

p-value

51.9% (27/52)
0.96±1.25 (52)

24.2% (55/227)
0.44±1.16 (227)

< 0.0001
0.0047

92.3% (48/52)

74.4% (169/227)

0.0052

2.02±0.94 (52)

1.52±1.13 (227)

0.0034

Jo

ur

na
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of

Variable
ED visits for asthma in the 12
months prior to study entry
% subjects with ED visits
# ED visits
Pulses of oral/IV steriods for asthma
in the 12 months prior to study entry
% subjects with pulses of oral/IV
steriods
# pulses of oral/IV steriods

Terminated
Subjects
(N = 52)
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Table 3. Control of severe exacerbations for subjects with 0, ≤1, and ≥2 severe exacerbations 12 months prior
to BT treatment (for the 227 subjects with a 5-year follow-up).
5-year subjects with
≥2 SEs in 12 months
prior to BT

0 or 1 SEs for
each year from
years 1 to 5

61.8% (68/110)

35.0% (41/117)

≥2 SEs in at
least one year
from years 1 to
5

38.2% (42/110)

65.0% (76/117)

of

5-year subjects with
≤1 SEs in 12 months
prior to BT
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ro

SE, severe exacerbation
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Table 4. Medication Usage in PAS2 Subjects.
Baseline
(N=279)

1 Year
(N=261)

2 Years
(N=244)

3 Years
(N=239)

4 Years
(N=221)

5 Years
(N=227)

ICS Dose (μg/day)

2272±787 (278)

2080±933 (253)

1910±1004 (234)

1979±1065 (225)

1926±1180 (207)

1928±1200 (206)

LABA Dose (μg/day)

105.3±40.6 (278)

106.8±77.1 (247)

98.8±45.2 (222)

102.9±83.5 (216)

109.3±105.4 (196)

101.7±77.8 (198)

2.4±1.5 (264)

2.4±1.5 (246)

2.4±1.6 (233)

2.4±1.6 (227)

2.4±1.7 (210)

2.4±1.6 (213)

19.4% (54/279)

10.7% (28/261)

10.2% (25/244)

10.0% (24/239)

8.1% (18/221)

9.7% (22/227)

SABA (puffs/day)
OCS

8.8±2.8 (52)

8.3±3.0 (26)

12.8±6.8 (25)

12.6±8.8 (23)

13.0±6.6 (17)

11.3±5.8 (21)

5.0% (14/279)

3.8% (10/261)

5.3% (13/244)

5.9% (14/239)

4.5% (10/221)

4.4% (10/227)

Leukotriene
Modifiers

49.5% (138/279)

48.3% (126/261)

45.9% (112/244)

46.9% (112/239)

47.5% (105/221)

44.9% (102/227)

Any biologic

15.8% (44/279)

15.3% (40/261)

14.8% (36/244)

17.2% (41/239)

19.9% (44/221)

18.5% (42/227)

Dose (mg/day)
Methylxanthines

15.8% (44/279)

14.9% (39/261)

14.3% (35/244)

14.6% (35/239)

13.1% (29/221)

10.6% (24/227)

0.0% (0/279)

0.4% (1/261)

0.0% (0/244)

2.1% (5/239)

5.9% (13/221)

6.6% (15/227)

Benralizumab

0.0% (0/279)

0.0% (0/261)

0.4% (1/244)

0.4% (1/239)

0.9% (2/221)

0.9% (2/227)

Reslizumab

0.0% (0/279)

0.0% (0/261)

0.0% (0/244)

0.0% (0/221)

0.4% (1/227)

26.2% (73/279)

28.4% (74/261)

28.3% (69/244)

34.4% (76/221)

33.5% (76/227)

ro

-p

0.0% (0/239)

31.0% (74/239)

lP

re

Other asthmarelated medications
(anticholinergics,
mast cell stabilizers)

of

Omalizumab
Mepolizumab

Numbers are: mean ± standard deviation (sample size) or % (x/N)

Jo

ur

na

Abbreviations: ICS, inhaled corticosteroids; LABA, long-acting -agonist; OCS, oral corticosteroids; SABA, short-acting
-agonists
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Table 5. Respiratory-related adverse events in PAS2 Subjects
Subject with ≥1
event [n (%)]

Events /
Subject

279
276
262
250
240
235

63
39
29
25
15
13

41 (14.7%)
26 (9.4%)
25 (9.5%)
17 (6.8%)
10 (4.2%)
11 (4.7%)

0.23
0.14
0.11
0.10
0.06
0.06

279
276
262
250
240
235

815
470
397
321
324
287

233 (83.5%)
184 (66.7%)
165 (63.0%)
155 (62.0%)
141 (58.8%)
133 (56.6%)

2.92
1.70
1.52
1.28
1.35
1.22

of

Total #
Events

ro

Respiratory-related
SAEs
Treatment phase a
Year 1 Post-treatment b
Year 2 Post-treatment b
Year 3 Post-treatment b
Year 4 Post-treatment b
Year 5 Post-treatment b
Respiratory-related AEs
Treatment phase a
Year 1 Post-treatment b
Year 2 Post-treatment b
Year 3 Post-treatment b
Year 4 Post-treatment b
Year 5 Post-treatment b

#
Subjects

a The

re

-p

treatment period is from first bronchoscopy to 6 weeks after last bronchoscopy. Yearly periods are 365 days times the number of years after the
treatment period.
b Subjects that have completed a 6-week follow-up visit at least 42 days after last bronchoscopy or any annual follow-up visit or started an AE at least
42 days after last bronchoscopy.
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lP

Abbreviations: AE, adverse event; SAE, serious adverse event
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